Results 121 to 130 of about 969,782 (213)

Spinal Metastases and the Evolving Role of Molecular Targeted Therapy, Chemotherapy, and Immunotherapy. [PDF]

Neurospine, 2022
Fomchenko EI, Bayley JC, Alvarez-Breckenridge C, Rhines LD, Tatsui CE.   +4 more
europepmc   +1 more source

Delayed pharyngocutaneous fistula caused by molecular targeted therapy: a case report. [PDF]

J Med Case Rep, 2022
Matsuo M, Hashimoto K, Jiromaru R, Nakagawa T.   +3 more
europepmc   +1 more source

The advanced development of molecular targeted therapy for hepatocellular carcinoma. [PDF]

Cancer Biol Med, 2022
Yan T, Yu L, Zhang N, Peng C, Su G, Jing Y, Zhang L, Wu T, Cheng J, Guo Q, Shi X, Lu Y.   +11 more
europepmc   +1 more source

Research progress in molecular targeted therapy for inflammatory bowel disease. [PDF]

J Transl Med
Liu N, Pan C, Qu L.
europepmc   +1 more source

Multifunctional Nanoplatform Based on Sunitinib for Synergistic Phototherapy and Molecular Targeted Therapy of Hepatocellular Carcinoma. [PDF]

Micromachines (Basel), 2023
Xu W, Yang M, Du X, Peng H, Yang Y, Wang J, Zhang Y.   +6 more
europepmc   +1 more source

Molecular Targeted Therapy for Chronic Non-Bacterial Mastitis: New Insights into Pathophysiology and Therapeutic Strategies. [PDF]

Int J Womens Health
Xuan Z, Zheng K, Zhang D, Wei H.
europepmc   +1 more source

Molecular-targeted therapy in ameloblastoma: a systematic review. [PDF]

Arch Craniofac Surg
Sulistyani LD, Julia V, Ariawan D, Latief MA, Utomo YA, Aboy, Ghaisani A, Fadhliana D, Mas'ud NW.   +8 more
europepmc   +1 more source

Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia. [PDF]

Biomedicines, 2022
Arai H, Minami Y, Chi S, Utsu Y, Masuda S, Aotsuka N.   +5 more
europepmc   +1 more source

Molecular targeted therapy in combination with chemotherapy for the treatment of platinum-resistant/refractory ovarian cancer (PROC): a systematic review and network meta-analysis. [PDF]

Ann Med
Ying T, E S, Ying H.
europepmc   +1 more source

Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC. [PDF]

Cancer Immunol Immunother, 2023
Li T, Guo J, Liu Y, Du Z, Guo Z, Fan Y, Cheng L, Zhang Y, Gao X, Zhao Y, He X, Wu W, Gao N, Wu Y, Li J, Zhang Y, Kang W, Cai Z, Wang W, Li X, Zan Y, Nguyen MH, Ji F.   +22 more
europepmc   +1 more source